Type 1 diabetes, COVID-19 vaccines and short-term safety: Subgroup analysis from the global COVAD study.

Chatterjee T, Ravichandran N, Nair N, Gracia-Ramos AE, Barman B, Sen P, Joshi M, Saha S, Nune A, Pande AKR, Velikova T, Parodis I, Tan AL, Shinjo SK, Boro H, Agarwal V, Aggarwal R, Gupta L (2024)

Publication Type: Journal article

Publication year: 2024

Journal

Book Volume: 15

Pages Range: 131-138

Journal Issue: 1

DOI: 10.1111/jdi.14079

Abstract

AIMS/INTRODUCTION: Coronavirus disease 2019 (COVID-19) vaccinations have been proven to be generally safe in healthy populations. However, the data on vaccine safety in patients with type 1 diabetes are scarce. This study aimed to evaluate the frequency and severity of short-term (<7-day) adverse vaccination events (AEs) and their risk factors among type 1 diabetes patients. MATERIALS AND METHODS: This study analyzed data from the COVID-19 vaccination in Autoimmune Diseases (COVAD) survey database (May to December 2021; 110 collaborators, 94 countries), comparing <7-day COVID-19 vaccine AE among type 1 diabetes patients and healthy controls (HCs). Descriptive statistics; propensity score matching (1:4) using the variables age, sex and ethnicity; and multivariate analyses were carried out. RESULTS: This study analyzed 5,480 completed survey responses. Of all responses, 5,408 were HCs, 72 were type 1 diabetes patients (43 females, 48.0% white European ancestry) and Pfizer was the most administered vaccine (39%). A total of 4,052 (73.9%) respondents had received two vaccine doses. Patients with type 1 diabetes had a comparable risk of injection site pain, minor and major vaccine AEs, as well as associated hospitalizations to HCs. However, type 1 diabetes patients had a higher risk of severe rashes (3% vs 0.4%, OR 8.0, 95% confidence interval 1.7-36), P = 0.007), although reassuringly, these were rare (n = 2 among type 1 diabetes patients). CONCLUSIONS: COVID-19 vaccination was safe and well tolerated in patients with type 1 diabetes with similar AE profiles compared with HCs, although severe rashes were more common in type 1 diabetes patients.

Involved external institutions

University of Illinois at Chicago United States (USA) (US) Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS) India (IN) The Royal Wolverhampton NHS Trust / Royal Wolverhampton Hospitals NHS Trust United Kingdom (GB) Instituto Mexicano del Seguro Social Mexico (MX) Maulana Azad Medical College (MAMC) India (IN) Byramjee Jeejeebhoy Government Medical College & Sassoon General Hospital India (IN) Southport and Ormskirk Hospital NHS Trust United Kingdom (GB) LEDTC Clinic India (IN) Sofia University "St. Kliment Ohridski" / Софийски университет "Св. Климент Охридски" Bulgaria (BG) NIHR Leeds Musculoskeletal Biomedical Research Unit (LMBRU) United Kingdom (GB) All India Institute of Medical Sciences India (IN) Mymensingh Medical College / ময়মনসিংহ মেডিকেল কলেজ Bangladesh (BD) Karolinska University Hospital / Karolinska Universitetssjukhuset Sweden (SE) University of São Paulo / Universidade de São Paulo (USP) Brazil (BR) University of Pittsburgh United States (USA) (US)

How to cite

APA:

Chatterjee, T., Ravichandran, N., Nair, N., Gracia-Ramos, A.E., Barman, B., Sen, P.,... Gupta, L. (2024). Type 1 diabetes, COVID-19 vaccines and short-term safety: Subgroup analysis from the global COVAD study. Journal of Diabetes Investigation, 15(1), 131-138. https://dx.doi.org/10.1111/jdi.14079

MLA:

Chatterjee, Tulika, et al. "Type 1 diabetes, COVID-19 vaccines and short-term safety: Subgroup analysis from the global COVAD study." Journal of Diabetes Investigation 15.1 (2024): 131-138.

BibTeX: Download